JAZZ PHARMS
SpecialtyJAZZ PHARMS is a specialty pharmaceutical company focused on Oncology, Respiratory, Gastroenterology. Key products include DEFITELIO.
FDA Novel Drug Designations
(2016-2024)JAZZ PHARMS at a Glance
- Fast trial execution (21 months median completion)
Upcoming FDA Decisions
Full Calendar →JAZZ PHARMS's Key Drugs
JAZZ PHARMS's core commercial portfolio centers on RYLAZE, DEFITELIO, ZIIHERA, spanning Oncology and Respiratory — its most strategically important drugs approved in the last 15 years.
JAZZ PHARMS's Recent FDA Approvals
JAZZ PHARMS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
JAZZ PHARMS's Therapeutic Areas
JAZZ PHARMS's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Respiratory, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
JAZZ PHARMS's Top Competitors
JAZZ PHARMS's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
JAZZ PHARMS Pipeline Snapshot
Active clinical trials for JAZZ PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 27/40 completed
- • Speed: 21 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2002-07-17
- Latest
- 2025-07-28
- Applications
- 5
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges